financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Keeps Hold Opinion On Shares Of Jones Lang Lasalle Incorporated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Keeps Hold Opinion On Shares Of Jones Lang Lasalle Incorporated
May 6, 2024 8:19 AM

10:55 AM EDT, 05/06/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price by $6 to $193 on a forward P/E of 16.0x our 2024 EPS estimate, a premium to JLL's 10-year average (14.4x) due to our expectations for an improvement in real estate transaction and leasing activity moving forward. We raise our 2024 EPS estimate by $0.27 to $12.08 and keep 2025's at $15.20. JLL posted Q1 2024 EPS of $1.78 vs. $0.71, a $0.92 consensus beat. Revenues rose 12% Y/Y, driven by Work Dynamics (+13% Y/Y, 72% of revenue), Capital Markets (+6% Y/Y, 7%), and Markets Advisory (+5% Y/Y, 19%), partially offset by JLL Technologies (-12% Y/Y, 1%) and LaSalle (-10% Y/Y, 2%). Total operating expenses rose 7% Y/Y, with work dynamics expenses +10% Y/Y. The CRE market remains challenged in the U.S. as high interest rates are continuing to result in delayed decision making, with buyers and sellers still struggling to come together. While large deal volume has started to improve, it remains well below longer-term averages. Leverage of 1.9x remains moderate, but up from 1.6x Q/Q.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Research Alert: CFRA Raises Opinion On Health Care To Marketweight From Underweight
Oct 8, 2025
01:40 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Pfizer Inc. (PFE 26 ****) and the U.S. government struck the first Most Favored Nation (MFN) drug pricing deal to lower drug prices in the U.S., we see policy...
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Ferrari N.v.
Oct 9, 2025
10:15 AM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $350, based on a 2026 P/E of 30x, a justified discount to RACE's 10-year average forward P/E multiple of 40x. Our adjusted EPS estimates...
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Research Alert: CFRA Lowers Opinion On Real Estate To Underweight From Marketweight
Oct 8, 2025
02:20 PM EDT, 10/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We are lowering our opinion on the Real Estate sector to underweight given its vulnerability to potential disappointment if Fed rate cuts prove less aggressive than market expectations, combined with...
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Pepsico, Inc.
Oct 9, 2025
01:45 PM EDT, 10/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target of $170, based on a 2026 P/E of 20.2x, a justified discount to PEP's five-year mean forward P/E of 23.0x. We maintain our adjusted EPS...
Copyright 2023-2025 - www.financetom.com All Rights Reserved